Clinical Trials Using Cabozantinib S-malate

Clinical trials are research studies that involve people. The clinical trials on this list are studying Cabozantinib S-malate. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-25 of 37
1 2 Next >

  • Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that have spread to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.
    Location: 517 locations

  • Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

    This phase II trial compares cabozantinib alone and the combination of cabozantinib and nivolumab to standard chemotherapy in the treatment of patients with non-squamous non-small cell lung cancer (NSCLC). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ramucirumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as docetaxel, gemcitabine hydrochloride, paclitaxel, and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving cabozantinib alone or in combination with nivolumab may be more effective than standard chemotherapy in treating patients with non-small cell lung cancer.
    Location: 357 locations

  • Testing Cabozantinib in Patients with Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

    This randomized phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that have spread to other places in the body (advanced). Cabozantinib is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.
    Location: 361 locations

  • Cabozantinib-S-Malate in Treating Younger Patients with Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

    This phase II trial studies how well cabozantinib-s-malate works in treating younger patients with sarcomas, Wilms tumor, or other rare tumors that have come back, do not respond to therapy, or are newly diagnosed. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for tumor growth and tumor blood vessel growth.
    Location: 135 locations

  • Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

    This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types, including advanced urothelial carcinoma (UC) (including bladder, renal pelvis, ureter, urethra), renal cell carcinoma (RCC), castration-resistant prostate cancer (CRPC), non-small-cell lung cancer (NSCLC), triple negative breast cancer (TNBC), ovarian cancer (OC), endometrial cancer (EC), hepatocellular cancer (HCC), gastric cancer / gastroesophageal junction cancer / lower esophageal cancer (GC / GEJC / LEC), colorectal cancer (CRC), head and neck (H&N) cancer, and differentiated thyroid cancer (DTC). The study consists of two stages: in the Dose Escalation Stage, an appropriate recommended cabozantinib dose for the combination with standard dosing regimen of atezolizumab will be established; in the Expansion Stage, tumor-specific cohorts will be enrolled in order to further evaluate the safety and efficacy of the combination treatment in these tumor indications. Three exploratory single-agent cabozantinib (SAC) cohorts may also be enrolled with UC, NSCLC, or CRPC subjects. One exploratory single-agent atezolizumab (SAA) cohort may also be enrolled with CRPC subjects. Subjects enrolled in the SAC cohorts and SAA cohort may receive combination treatment with both cabozantinib and atezolizumab after they experience radiographic progressive disease per the Investigator per RECIST 1.1. Due to the nature of this study design, some tumor cohorts may complete enrollment earlier than others.
    Location: 31 locations

  • A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy

    The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid Cancer (DTC) who have progressed after prior VEGFR-Targeted therapy.
    Location: 17 locations

  • Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

    This phase II trial studies how well cabozantinib, nivolumab, and ipilimumab work in treating patients with differentiated thyroid cancer that does not respond to radioactive iodine and that worsened after treatment with a drug targeting the vascular endothelial growth factor receptor (VEGFR), a protein needed to form blood vessels. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab and ipilimumab may work better than the usual approach consisting of chemotherapy with drugs such as doxorubicin, sorafenib, and lenvatinib for this type of thyroid cancer.
    Location: 13 locations

  • Cabozantinib S-malate in Treating Patients with Plexiform Neurofibromas or Neurofibromatosis Type 1

    This phase II trial studies how well cabozantinib S-malate works in treating patients with plexiform neurofibromas or neurofibromatosis type 1. Cabozantinib S-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 13 locations

  • Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

    This phase II trial studies how well the combination of XL184 (cabozantinib), nivolumab, and ipilimumab work in treating patients with poorly differentiated neuroendocrine tumors (i.e., neuroendocrine tumor that does not look like the normal tissue it arose from). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab and ipilimumab may shrink the cancer.
    Location: 14 locations

  • Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy

    This Phase 3 study evaluates the safety and efficacy of cabozantinib in combination with atezolizumab versus the standard of care sorafenib in adults with advanced hepatocellular carcinoma (HCC) who have not received previous systemic anticancer therapy. A single-agent cabozantinib arm will be enrolled in which subjects receive single agent cabozantinib in order to determine its contribution to the overall safety and efficacy of the combination with atezolizumab.
    Location: 11 locations

  • Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, the RadiCaL Study

    This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone. Radioactive drugs such as radium-223 dichloride may directly target radiation to cancer cells and minimize harm to normal cells. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving radium-223 dichloride and cabozantinib may help lessen the pain and symptoms from renal cell cancer that has spread to the bone, compared to cabozantinib alone.
    Location: 10 locations

  • Cabozantinib S-malate and Cetuximab in Treating Patients with Recurrent or Metastatic Head and Neck Squamous Cell Cancer

    This phase I trial studies the side effects and best dose of cabozantinib S-malate when given together with cetuximab in treating patients with head and neck squamous cell cancer that has come back (recurrent) or has spread to other places in the body (metastatic). Cabozantinib S-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab, may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib S-malate and cetuximab may work better in treating patients with recurrent or metastatic head and neck squamous cell cancer.
    Location: 9 locations

  • Nivolumab and Cabozantinib S-malate in Treating Patients with Advanced or Metastatic Kidney Cancer

    This phase II trial studies how well nivolumab and cabozantinib s-malate work in treating patients with kidney cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving nivolumab and cabozantinib s-malate may work better in treating patients with advanced or metastatic kidney cancer.
    Location: 7 locations

  • Cabozantinib-s-malate in Treating Patients with Non-small Cell Lung Cancer That Is Metastatic or Cannot Be Removed by Surgery

    This phase II trial studies how well cabozantinib-s-malate works in treating patients with non-small cell lung cancer that has spread to other parts of the body (metastatic) or cannot be removed by surgery. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 7 locations

  • Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma

    This phase II trial studies how well paclitaxel with and without nivolumab works in treating patients with soft tissue sarcoma that have not received taxane drugs, and how well nivolumab and cabozantinib work in treating taxane pretreated patients with soft tissue sarcoma. Nivolumab works through the body’s immune system to help the immune system act against tumor cells. Chemotherapy drugs, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This trial is being done to see if the combination of nivolumab and paclitaxel or cabozantinib can shrink soft tissue sarcoma and possibly prevent it from coming back.
    Location: 6 locations

  • Pembrolizumab and Cabozantinib S-malate in Treating Patients with Locally Advanced, Recurrent, or Metastatic Kidney Cancer

    This phase I / II trial studies how well cabozantinib s-malate works when given together with pembrolizumab in treating patients with kidney cancer that has come back, spread from where it started to nearby tissue or lymph nodes, or spread to other places in the body. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and cabozantinib s-malate may work better in treating patients with renal cell carcinoma.
    Location: 4 locations

  • Pembrolizumab and Cabozantinib in Treating Patients with Recurrent or Metastatic Head and Neck Squamous Cell Cancer That Cannot Be Removed by Surgery

    This phase II trial studies how well pembrolizumab and cabozantinib work in treating patients with head and neck squamous cell cancer that has come back (recurrent) or spread to other places in the body (metastatic) and cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozntinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and cabozantinib may work better in treating patients with head and neck squamous cell cancer.
    Location: 3 locations

  • Cabozantinib S-malate and Nivolumab with or without Ipilimumab in Treating Patients with Metastatic Genitourinary Tumors

    This phase I trial studies the side effects and best doses of cabozantinib s-malate and nivolumab with or without ipilimumab in treating patients with genitourinary (genital and urinary organ) tumors that have spread to other places in the body (metastatic). Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving cabozantinib s-malate and nivolumab alone or with ipilimumab works better in treating patients with genitourinary tumors.
    Location: 8 locations

  • Cabozantinib and Nivolumab for the Treatment of Advanced Carcinoid Tumors

    This phase II trial studies how well cabozantinib and nivolumab work in treating patients with carcinoid tumors that have spread to other places in the body (advanced). Carcinoid tumor is another term used to refer to neuroendocrine tumors that arise in organs such as the gastrointestinal tract, lungs, or thymus. Cabozantinib works by blocking the growth of new blood vessels (angiogenesis) that help to feed a tumor. In addition to blocking the formation of new blood cells in tumors, cabozantinib also blocks pathways that may be responsible for allowing tumor cells to become resistant to other anti-angiogenic cancer drugs. Nivolumab works by attaching to and blocking a molecule called PD-1. PD-1 is a protein that is present on different types of cells in the immune system and controls parts of the immune system by shutting it down. Antibodies that block PD-1 may prevent PD-1 from shutting down the immune system, thus allowing it to recognize and help the body destroy the tumor cells. The purpose of this study is to test the safety and effectiveness of cabozantinib in combination with nivolumab in treating advanced carcinoid tumors.
    Location: 2 locations

  • Cabozantinib and Isotretinoin in Treating Children with Relapsed or Refractory Solid Tumors

    This phase I trial studies the best dose and side effects of cabozantinib when given in combination with isotretinoin in treating children with solid tumors that have come back (relapsed) or do not respond to treatment (refractory). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Isotretinoin is a drug closely related to vitamin A and it may to help stop the growth and spread of tumor cells. Giving cabozantinib and isotretinoin may work better at treating solid tumors.
    Location: 2 locations

  • Cabozantinib and Pembrolizumab as First Line Therapy in Treating Patients with Cisplatin-Ineligible Metastatic, Locally Advanced, or Unresectable Urothelial Cancer

    This phase II trial studies the side effects and best dose of cabozantinib when given together with pembrolizumab and how well it works as first line therapy in treating patients with cisplatin-ineligible urothelial cancer that has spread to nearby tissue or lymph nodes (locally advanced) or has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib and pembrolizumab may work better in treating patients with cisplatin-ineligible metastatic, locally advanced, or unresectable urothelial cancer.
    Location: 3 locations

  • Cabozantinib, Ipilimumab, Nivolumab, and Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma

    This phase II trial investigates how well cabozantinib, ipilimumab, nivolumab, and transarterial chemoembolization (TACE) work in treating patients with hepatocellular carcinoma. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. TACE is a procedure that blocks or slows down the blood supply to the cancer and delivers chemotherapy directly to the tumor so that the tumor cells die. TACE is done by injecting a material through a thin tube (called a catheter) into the large blood vessels that are feeding the tumor. The material blocks the arteries and delivers chemotherapy to the tumor. Giving cabozantinib, ipilimumab, nivolumab, and TACE together may control the disease longer than the standard (usual) treatment.
    Location: UC Irvine Health / Chao Family Comprehensive Cancer Center, Orange, California

  • Cabozantinib with Radiation Therapy for the Treatment of Sarcomas of the Extremities

    This phase I / II trial studies the side effects and best dose of cabozantinib when given with radiation therapy and how well it works in treating patients with sarcoma of the extremities. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving cabozantinib with radiation therapy may make the tumors smaller and reduce the amount of normal tissue that needs to be removed.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • Cabozantinib in Treating Patients with Locally Advanced Non-metastatic Kidney Cancer

    This phase II trial studies how well cabozantinib works in treating patients with kidney cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) and not to other places in the body (non-metastatic). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This study is being done to see if cabozantinib is effective in kidney cancer before surgery.
    Location: Emory University Hospital / Winship Cancer Institute, Atlanta, Georgia

  • Immediate Prostatectomy versus Cabozantinib Followed by Prostatectomy in Patients with Intermediate-High or High-Risk Prostate Cancer, The SPARC Study

    This phase II trial studies different biomarkers to gain a better understanding of how cabozantinib affects prostate cancer and the immune system in patients with intermediate-high or high-risk prostate cancer undergoing radical prostatectomy. Radical prostatectomy is a surgical procedure to remove the entire prostate and some of the tissue surrounding it. A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Biomarkers, obtained from blood and prostate tissue, include proteins (building blocks of the body, cells, and organs) involved in tumor growth and immune system activation, as well as genetic changes. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The purpose of this study is to determine the effect that cabozantinib has on these biomarkers and prostate cancer by comparing prostatectomy tissue and blood samples from patients who received cabozantinib to those who did not receive cabozantinib prior to prostatectomy. This study will also evaluate the safety and efficacy of cabozantinib in subjects with prostate cancer who are undergoing prostatectomy.
    Location: Duke University Medical Center, Durham, North Carolina


1 2 Next >